INTUITIVE SURGICAL INC

Intuitive Surgical’s ISRG stock shows strong 397% 10‑year growth, high GF score, and a 23% upside target, but DCF overvaluation and AI‑robotics competition raise caution.

Explore how Intuitive Surgical’s da Vinci and Ion robotics are driving revenue growth, precision surgery, and investor confidence in the booming surgical tech market.

Intuitive Surgical’s recent executive stock sales spark investor curiosity as the company’s share price fluctuates and calls for more transparency amid a competitive medical‑equipment market.

Intuitive Surgical’s earnings reveal the future of surgical tech: market‑cap $144B, 49.44 P/E, and analyst‑surprise potential amid economic uncertainty.

Intuitive Surgical’s latest earnings beat forecasts, boosting its stock and reinforcing the demand for its robotic surgical systems.

Intuitive Surgical’s share price surged 448% in 10 years, topping $400 today, yet analysts debate its high PE and future growth amid market volatility.

Intuitive Surgical’s $147 bn market cap shows a tech‑driven growth story—5‑year gains hit 43 %, yet a DCF puts the stock at $196, raising the valuation debate. Explore the upside and risks of this surgical‑robotics leader.

Intuitive Surgical’s leadership shake‑up: Taylor Patton’s promotion to chief commercial officer boosts da Vinci and Ion growth, while Henry Charlton refines operations, positioning ISRG for aggressive expansion and investor confidence amid market di…

Intuitive Surgical Q1 2026 earnings beat shows da Vinci 5 drives 25 % revenue growth, 28 % margin, and strong analyst upside—growth story that’s hard to copy.

Intuitive Surgical’s Q1 2026 earnings may spark a turnaround as the company targets a growing robotic‑surgery market, focusing on sales velocity, repeat orders, and service revenue.